Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite

Open access
Albulescu, Laura-Oana, Xie, Chunfang, Ainsworth, Stuart, Alsolaiss, Jaffer, Crittenden, Edouard, Dawson, Charlotte A., Softley, Rowan, Bartlett, Keirah E., Harrison, Robert A., Kool, Jeroen, Casewell, Nicholas R. · 2020 · Nature Communications

Published version of a preprint

Abstract

Snakebite is a medical emergency causing high mortality and morbidity in rural tropical communities that typically experience delayed access to unaffordable therapeutics. Viperid snakes are responsible for the majority of envenomings, but extensive interspecific variation in venom composition dictates that different antivenom treatments are used in different parts of the world, resulting in clinical and financial snakebite management challenges. Here, we show that a number of repurposed Phase 2-approved small molecules are capable of broadly neutralizing distinct viper venom bioactivities in vitro by inhibiting different enzymatic toxin families. Furthermore, using murine in vivo models of envenoming, we demonstrate that a single dose of a rationally-selected dual inhibitor combination consisting of marimastat and varespladib prevents murine lethality caused by venom from the most medically-important vipers of Africa, South Asia and Central America. Our findings support the translation of combinations of repurposed small molecule-based toxin inhibitors as broad-spectrum therapeutics for snakebite.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-19981-6

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 67

  1. Gutiérrez, J. M. et al. Snakebite envenoming. Nat. Rev. Dis. Prim. 3, 17063 (2017). · DOI · Paper page
  2. Harrison, R. A., Casewell, N. R., Ainsworth, S. A. & Lalloo, D. G. The time is now: a call for action to translate recent momentum on tackling tropical snakebite into sustained benefit for victims. Trans. R. Soc. Trop. Med. Hyg. 113, 835–838 (2019). · DOI
  3. Williams, D. J. et al. Strategy for a globally coordinated response to a priority neglected tropical disease: Snakebite envenoming. PLoS Negl. Trop. Dis. 13, e0007059 (2019). · DOI · Paper page
  4. Casewell, N. R. et al. Medically important differences in snake venom composition are dictated by distinct postgenomic mechanisms. Proc. Natl Acad. Sci. USA 111, 9205–9210 (2014). · DOI · Paper page
  5. Tasoulis, T. & Isbister, G. K. A review and database of snake venom proteomes. Toxins 9, 290 (2017). · DOI · Paper page
  6. Williams, D. J. et al. Ending the drought: New strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. J. Proteom. 74, 1735–1767 (2011). · DOI · Paper page
  7. Arnold, C. Vipers, mambas and taipans: the escalating health crisis over snakebites. Nature 537, 26–28 (2016). · DOI
  8. Gutiérrez, J. M. Global availability of antivenoms: The relevance of public manufacturing laboratories. Toxins 11, 5 (2019). · doi:10.3390/toxins11010005
  9. Casewell, N. R. et al. Pre-clinical assays predict pan-African Echis viper efficacy for a species-specific antivenom. PLoS Negl. Trop. Dis. 4, e851 (2010). · DOI
  10. de Silva, H. A. et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: A randomised, double-blind, placebo-controlled trial. PLoS Med. 8, e1000435 (2011). · DOI · Paper page
  11. Mohapatra, B. et al. Snakebite mortality in India: a nationally representative mortality survey. PLoS Negl. Trop. Dis. 5, e1018 (2011). · DOI · Paper page
  12. Bulfone, T. C., Samuel, S. P., Bickler, P. E. & Lewin, M. R. Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite. J. Trop. Med. 2018, 1–14 (2018). · DOI
  13. Knudsen, C. & Laustsen, A. H. Recent advances in next generation snakebite antivenoms. Trop. Med. Infect. Dis 3, 42 (2018). · DOI
  14. Habib, A. G., Gebi, U. I. & Onyemelukwe, G. C. Snake bite in Nigeria. Afr. J. Med. &. Med. Sci. 30, 171–178 (2001).
  15. Otero-Patiño, R. Epidemiological, clinical and therapeutic aspects of Bothrops asper bites. Toxicon 54, 998–1011 (2009). · DOI · Paper page
  16. Kumar, K. G. S., Narayanan, S., Udayabhaskaran, V. & Thulaseedharan, N. K. Clinical and epidemiologic profile and predictors of outcome of poisonous snake bites – an analysis of 1,500 cases from a tertiary care center in Malabar, North Kerala, India. Int. J. Gen. Med. 11, 209–216 (2018). · DOI
  17. Slagboom, J., Kool, J., Harrison, R. A. & Casewell, N. R. Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise. Br. J. Haematol. 177, 947–959 (2017). · DOI · Paper page
  18. Gutiérrez, J. M. & Rucavado, A. Snake venom metalloproteinases: their role in the pathogenesis of local tissue damage. Biochimie 82, 841–850 (2000). · DOI · Paper page
  19. Gutiérrez, J. M., Escalante, T., Rucavado, A. & Herrera, C. Hemorrhage caused by snake venom metalloproteinases: a journey of discovery and understanding. Toxins (Basel). 8, 93 (2016). · DOI · Paper page
  20. Ferraz, C. R. et al. Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis. Front. Ecol. Evol. 7, 1–19 (2019). · DOI · Paper page
  21. Howes, J.-M., Theakston, R. D. G. & Laing, G. D. Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators. Toxicon 49, 734–739 (2007). · DOI
  22. Lewin, M., Samuel, S., Merkel, J. & Bickler, P. Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation. Toxins 8, 248 (2016). · DOI · Paper page
  23. Arias, A. S., Rucavado, A. & Gutiérrez, J. M. Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom. Toxicon 132, 40–49 (2017). · DOI
  24. Rucavado, A. et al. Inhibition of local hemorrhage and dermonecrosis induced by Bothrops asper snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA. Am. J. Trop. Med. Hyg. 63, 313–319 (2000). · DOI
  25. Ainsworth, S. et al. The paraspecific neutralisation of snake venom induced coagulopathy by antivenoms. Commun. Biol. 1, 34 (2018). · DOI
  26. Lewin, M. et al. Delayed LY333013 (Oral) and LY315920 (Intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of Micrurus fulvius (Eastern coral snake) venom. Toxins 10, 479 (2018). · DOI
  27. Lewin, M. et al. Delayed oral LY333013 rescues mice from highly neurotoxic, lethal doses of Papuan taipan (Oxyuranus scutellatus) venom. Toxins 10, 380 (2018). · DOI
  28. Albulescu, L.-O. et al. Preclinical validation of a repurposed metal chelator as an early-intervention therapeutic for hemotoxic snakebite. Sci. Trans. Med. 12, eaay8314 (2020). · DOI
  29. Wang, Y. et al. Exploration of the inhibitory potential of varespladib for snakebite envenomation. Molecules 23, 391 (2018). · DOI
  30. Layfield, H. J. et al. Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group I metalloprotease from the venom of the Western diamondback rattlesnake, Crotalus atrox. Toxins 12, 309 (2020). · DOI
  31. Rowsell, S. et al. Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. J. Mol. Biol. 319, 173–181 (2002). · DOI · Paper page
  32. Warrell, D. A. & Arnett, C. The importance of bites by the saw scaled or carpet viper (Echis carinatus): Epidemiological studies in Nigeria and a review of the world. Acta Trop. 33, 307–341 (1976).
  33. Warrell, D. in Handbook of Clinical Toxicology of Animal Venoms and Poisons (eds White, J. & Meier, J.) pp 534–594 (CRC Press, 1995).
  34. Warrell, D. in Handbook of Clinical Toxicology of Animal Venoms and Poisons (eds. White, J. & Meier, J.) pp 455–492 (CRC Press, 1995).
  35. Still, K. et al. Multipurpose HTS Coagulation Analysis: Assay Development and Assessment of Coagulopathic Snake Venoms. Toxins 9, 382 (2017). · DOI
  36. Rogalski, A. et al. Differential procoagulant effects of saw-scaled viper (Serpentes: Viperidae: Echis) snake venoms on human plasma and the narrow taxonomic ranges of antivenom efficacies. Toxicol. Lett. 280, 159–170 (2017). · doi:10.1016/j.toxlet.2017.08.020
  37. Slagboom, J. et al. High throughput screening and identification of coagulopathic snake venom proteins and peptides using nanofractionation and proteomics approaches. PLoS Negl. Trop. Dis. 14, e0007802 (2020). · DOI
  38. Winer, A., Adams, S. & Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol. Cancer Ther. 17, 1147–1155 (2018). · DOI · Paper page
  39. Kim, E. Y. et al. Low-dose nafamostat mesilate in hemodialysis patients at high bleeding risk. Kidney Res. Clin. Pract. 30, 61–66 (2011).
  40. Kim, H. S. et al. Cardiac arrest caused by nafamostat mesilate. Kidney Res. Clin. Pract. 35, 187–189 (2016). · doi:10.1016/j.krcp.2015.10.003
  41. Theakston, R. D. & Reid, H. A. Development of simple standard assay procedures for the characterization of snake venom. Bull. World Health Organ. 61, 949–956 (1983).
  42. Harrison, R. A. et al. Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa. PLoS Negl. Trop. Dis. 11, e0005969 (2017). · DOI
  43. Bolaños, R. Toxicity of Costa Rican snake venoms for the white mouse. Am. J. Trop. Med. Hyg. 21, 360–363 (1972). · DOI
  44. Villalta, M. et al. Development of a new polyspecific antivenom for snakebite envenoming in Sri Lanka: Analysis of its preclinical efficacy as compared to a currently available antivenom. Toxicon 122, 152–159 (2016). · DOI
  45. Mora-Obando, D. et al. Proteomic and functional profiling of the venom of Bothrops ayerbei from Cauca, Colombia, reveals striking interspecific variation with Bothrops asper venom. J. Proteom. 96, 159–172 (2014). · DOI
  46. Harrison, R. A. & Gutiérrez, J. M. Priority actions and progress to substantially and sustainably reduce the mortality, morbidity and socioeconomic burden of tropical snakebite. Toxins 8, 351 (2016). · DOI
  47. de la Rosa, G. et al. Horse immunization with short-chain consensus α-neurotoxin generates antibodies against broad spectrum of elapid venomous species. Nat. Commun. 10, 3642 (2019). · DOI
  48. Kini, R. M., Sidhu, S. S. & Laustsen, A. H. Biosynthetic oligoclonal antivenom (BOA) for snakebite and next-generation treatments for snakebite victims. Toxins 10, 534 (2018). · DOI
  49. Laustsen, A. H. et al. In vivo neutralization of dendrotoxin-mediated neurotoxicity of black mamba venom by oligoclonal human IgG antibodies. Nat. Commun. 9, 3928 (2018).
  50. Peterson, J. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc. Res. 69, 677–687 (2006). · DOI · Paper page
  51. Millar, A. W. et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br. J. Clin. Pharmacol. 45, 21–26 (1998). · doi:10.1046/j.1365-2125.1998.00639.x
  52. Rosemurgy, A. et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol. 22, 247–252 (1999). · DOI
  53. Adis R&D Profile. Varespladib. Am. J. Cardiovasc. Drugs 11, 137–143 (2011). · DOI · Paper page
  54. Rosenson, R. S. et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56, 1079–1088 (2010). · DOI
  55. Abraham, E. et al. Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit. Care Med. 31, 718–728 (2003). · DOI
  56. Nicholls, S. J. et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial. JAMA - J. Am. Med. Assoc. 311, 252–262 (2014). · DOI · Paper page
  57. Ohtake, Y. et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib. Nephrol. 93, 215–217 (1991). · doi:10.1159/000420222
  58. Maiorino, R. M., Xu, Z. F. & Aposhian, H. V. Determination and metabolism of dithiol chelating agents. XVII. In humans, sodium 2,3-dimercapto-1-propanesulfonate is bound to plasma albumin via mixed disulfide formation and is found in the urine as cyclic polymeric disulfides. J. Pharmacol. Exp. Ther. 277, 375–384 (1996).
  59. Kosnett, M. J. The role of chelation in the treatment of arsenic and mercury poisoning. J. Med. Toxicol. 9, 347–354 (2013). · doi:10.1007/s13181-013-0344-5
  60. Wagstaff, S. C., Sanz, L., Juárez, P., Harrison, R. A. & Calvete, J. J. Combined snake venomics and venom gland transcriptomic analysis of the ocellated carpet viper, Echis ocellatus. J. Proteom. 71, 609–623 (2009). · DOI
  61. Tan, N. H. et al. Functional venomics of the Sri Lankan Russell’s viper (Daboia russelii) and its toxinological correlations. J. Proteom. 128, 403–423 (2015). · DOI
  62. Pla, D. et al. Phylovenomics of Daboia russelii across the Indian subcontinent. Bioactivities and comparative in vivo neutralization and in vitro third-generation antivenomics of antivenoms against venoms from India, Bangladesh and Sri Lanka. J. Proteom. 207, 103443 (2019). · DOI
  63. Bradley, J. D. et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J. Rheumatol. 32, 417–423 (2005).
  64. Sevenet, P. O. & Depasse, F. Clot waveform analysis: Where do we stand in 2017? Int. J. Lab. Hematol. 39, 561–568 (2017). · DOI
  65. Patra, A., Kalita, B., Chanda, A. & Mukherjee, A. K. Proteomics and antivenomics of Echis carinatus carinatus venom: Correlation with pharmacological properties and pathophysiology of envenomation. Sci. Rep. 7, 17119 (2017). · DOI
  66. Alape-Girón, A. et al. Studies on the venom proteome of Bothrops asper: perspectives and applications. Toxicon 54, 938–948 (2009). · DOI
  67. Calvete, J. J., Escolano, J. & Sanz, L. Snake venomics of Bitis species reveals large intragenus venom toxin composition variation: application to taxonomy of congeneric taxa. J. Proteome Res. 6, 2732–2745 (2007). · DOI

Cited by

See all 174

Metadata

Authors
Albulescu, L.-O., Xie, C., Ainsworth, S., Alsolaiss, J., Crittenden, E., Dawson, C. A., Softley, R., Bartlett, K. E., Harrison, R. A., Kool, J., & Casewell, N. R.
Venue
Nature Communications
Published
2020-12-15
Volume
11
Issue
1
Pages
6094-6094
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3112999791
Cited by
174
References
2
FWCI
12.04
Type
journal article
Language
en
Open access
gold
Licence
Funders
  • Wellcome Trust (200517/Z/16/Z)
  • RCUK | Medical Research Council (MR/S00016X/1 and CiC19017)
  • Royal Society (200517/Z/16/Z)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. https://app.cochat.ai/papers/10.1038/s41467-020-19981-6
The paper
Albulescu, L.-O., Xie, C., Ainsworth, S., Alsolaiss, J., Crittenden, E., Dawson, C. A., Softley, R., Bartlett, K. E., Harrison, R. A., Kool, J., & Casewell, N. R. (2020). A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite. Nature Communications. https://doi.org/10.1038/s41467-020-19981-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.